Acoramidis Long-Term Data Reveals Near 50% Mortality Reduction in ATTR-CM
BBIO has more than doubled off its 52-week low of $28.325 on light trading volume (0.3× avg).
Summary
BridgeBio Pharma announced highly positive long-term efficacy and safety data for its approved drug, Acoramidis (Attruby), from the ATTRibute-CM open-label extension trial. The data showed a statistically significant 44.7% reduction in all-cause mortality and a 49.3% reduction in cardiovascular mortality in ATTR-CM patients through Month 54. This compelling long-term mortality benefit, presented at the ACC Annual Scientific Sessions & Expo and published in JAMA Cardiology, is a major differentiator for Acoramidis in the competitive ATTR-CM market. While the company's recent 10-K (2026-02-24) noted robust commercial success for Attruby, this specific long-term mortality data with such strong statistical significance is new and significantly enhances the drug's profile. Such strong clinical outcomes are likely to drive increased physician adoption and market share, strengthening the commercial outlook for this key product. Investors will monitor the impact of this data on Acoramidis's sales trajectory and competitive positioning.
At the time of this announcement, BBIO was trading at $69.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.4B. The 52-week trading range was $28.33 to $84.94. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.